经导管主动脉瓣植入术治疗狭窄和反流的主动脉瓣生物瓣 CoreValve 用于治疗失败的生物瓣主动脉瓣置换。

Transcatheter aortic valve implantation for stenosed and regurgitant aortic valve bioprostheses CoreValve for failed bioprosthetic aortic valve replacements.

机构信息

Sussex Cardiac Centre, Brighton and Sussex University Hospitals NHS Trust, Brighton, UK.

出版信息

J Am Coll Cardiol. 2010 Jan 12;55(2):97-101. doi: 10.1016/j.jacc.2009.06.060.

Abstract

Transcatheter aortic valve implantation is increasingly being used to treat severe aortic stenosis in patients with high operative risk. In an aging population the incidence of aortic stenosis is rising, and increasing numbers of elderly patients are undergoing aortic valve replacement with bioprosthetic valves. Therefore, there is a corresponding increase in prosthetic degeneration. This presents cardiologists with a cohort of patients for whom the risk of re-do aortic valve surgery is prohibitive. We present the first series of such patients with degenerative bioprosthetic stenosis or regurgitation successfully treated with CoreValve (Medtronic, Luxembourg) implantation.

摘要

经导管主动脉瓣植入术越来越多地用于治疗高手术风险的严重主动脉瓣狭窄患者。随着人口老龄化,主动脉瓣狭窄的发病率不断上升,越来越多的老年患者接受生物瓣置换主动脉瓣。因此,假体退行性变也相应增加。这给心脏病专家带来了一群再次进行主动脉瓣手术风险极高的患者。我们首次报告了一系列成功接受 CoreValve(美敦力,卢森堡)植入术治疗的退行性生物瓣狭窄或反流患者。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索